819TiP COLIBRI trial (GINECO-CE108b): A multicenter, window study evaluating immune impact and safety of nivolumab in combination with ipilimumab before initial radio-chemotherapy (RTCT) treatment for locally advanced cervix cancer

Abstract

Cervical cancer is the fourth most frequent cancer in women with a survival rate <20% for advanced stages. It mainly results from chronic infection with human papillomavirus. Standard first-line therapy is RTCT for cervical cancer FIGO stage IB3 and more. Recent evidence in pretreated advanced disease reported combined use of ipilimumab (anti-CTLA-4) with nivolumab (anti-PD-1) may have complementary action, thus yielding a highest clinical efficacy but is explored in heavily pretreated patients where immune resources could be altered.